TL62: Oncology Phase I Clinical Trial Designs: Can Current Approaches Be Improved To Increase Efficiency and Effectiveness?
*Serap Sankoh, Millennium Pharmaceuticals: The Takeda Oncolgy Company
Oncology Phase I Clinical Trials To Be Compared: Tradtional 3+3 Escalation Rules, Accelarated Titration, Bayesian Continual Reassessment Model, Bayesian Logistic Regression Model,and Ji's Bayes Method? Determining the optimal design under optimal conditions. The reasons why we choose one design over the others. Questions to be discussed at the roundtable discussion: 1) What is the industry standard for Oncology Phase I Clinical Design? Why do we chooce one design over the others? 2)What were the experiences with clinicians and regulatory agencies choosing one design over the others? 3) What were the obstacles?
April 30 - May 22, 2013
Invited Abstract Submission Open
June 4, 2013
Online Registration Opens
August 9 - August 23, 2013
Invited Abstract Editing
August 23, 2013
Short Course materials due from Instructors
August 26, 2013
September 9, 2013
Cancellation Deadline and Registration Closes @ 11:59 pm EDT
September 16 - September 18, 2013
Marriott Wardman Park, Washington, DC